Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


VUMC Studying Potential Approach to Reverse Precancerous Stomach Lesions


 

Vanderbilt University Medical Center (VUMC) cancer researcher James Goldenring, MD, PhD, has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New York, to begin clinical trials of a potential approach for reversing precancerous stomach lesions.

Stomach cancer is the fourth leading cause of cancer-related deaths worldwide after lung, liver and colorectal cancers. In the United States, 28,000 people will be diagnosed with stomach cancer this year, and nearly 11,000 will die from the disease, according to the American Cancer Society.

Goldenring said the grant will support an international collaborative trial with colleagues at Yonsei University Medical Center in Seoul, Korea, to test the effectiveness of the drug Selumetinib to reverse pre-cancerous lesions in patients following endoscopic resection of stage I gastric cancer. Koreans have one of the world's highest incidences of gastric cancer.

"I am extremely grateful for the support that we have received from the DeGregorio Family Foundation," said Goldenring, the Paul W. Sanger Professor of Experimental Surgery at Vanderbilt University School of Medicine. "It is often difficult to obtain support for trials that require clinical collaboration at international sites."

Selumetinib blocks MEK, an enzyme downstream of Ras, a signaling protein that regulates cell growth and survival. Abnormal Ras activation, possibly triggered by other signaling molecules, is associated with up to one-third of all human cancers and recently was identified in a large percentage of gastric cancers. A year ago, Goldenring reported in Gastroenterology that Selumetinib, a drug recently approved for use in patients with advanced thyroid cancer, halted and reversed neoplastic progression in a mouse model of activated Ras induction of metaplasia and precancerous lesions in the stomach.

It appears that underneath the abnormal metaplastic cells hides a lineage of normal progenitor cells, which can regenerate the normal mucosal layer of the stomach, Goldenring said. When the consequences of abnormal Ras activation were blocked by Selumetinib, normal cells pushed the abnormal tissue out of the mucosa. The grant will support a study of MEK inhibition in patients who have had local endoscopic removal of a stage I gastric cancer. These patients have a 2 to 5 percent per year incidence of developing a second cancer in the stomach because a large amount of metaplastic mucosa remains.

Astra-Zeneca Corporation will provide the Selumetinib for the trial. Goldenring is professor of Surgery and Cell & Developmental Biology, vice-chair for Surgical Research in the Section of Surgical Sciences and co-director of the Epithelial Biology Center at VUMC. He also is a staff physician at the Veterans Affairs Medical Center (Tennessee Valley Healthcare System, Nashville campus).

 
Share:

Related Articles:


Recent Articles

Maintaining a Medical Presence in Rural Tennessee

On March 1, another rural Tennessee hospital closed its doors for good, leaving yet another town without easy access to emergency care and inpatient services.

Read More

When Every Minute Matters

Nashville hospitals are setting higher standards for trauma outcomes.

Read More

Physician Spotlight: State of Health

TDH Commissioner Lisa Piercey, MD, is making prevention, rural healthcare a priority.

Read More

Sen. Alexander Recognized by AMA for Outstanding Service

Last month, the AMA recognized U.S. Senator Lamar Alexander for his work to improve healthcare across the country.

Read More

Small Towns, Big Fight for Continued Access to Care

Cuts and reimbursement changes have led to increased hospital closures in rural America, but the National Rural Health Association is working diligently to educate lawmakers on the vital role these facilities play in keeping a community healthy and vibrant.

Read More

Being Responsive to First Responders

First responders witness human tragedy on a routine basis. A train-the-trainer program led by Acadia CMO Dr. Michael Genovese looks to alert colleagues and supervisors to red flags of PTSI and create supports to foster resiliency.

Read More

Violence in U.S. Emergency Departments on the Rise

By their very nature, emergency departments are high-stakes settings filled with vulnerable patients and frightened families. Increasingly, they are also high-risk settings for healthcare providers.

Read More

NMGMA: 10 Minute Takeaway

Hackers continue to target healthcare providers because of the rich patient data that is part of a practice's files. Staying one step ahead is tough, but there are proactive steps to take.

Read More

Education through Innovation

From virtual classrooms to high-tech sim labs, VUSN offers state-of-the-art training for tomorrow's nurse practitioners.

Read More

Health Care Council Hosts Eyles, Kahn for Policy Discussion

The Nashville Health Care Council hosted a lively discussion on healthcare policy with leaders of two of the most influential healthcare advocacy groups in D.C.

Read More

Email Print
 
 

 

 


Tags:
cancer research, DeGregorio Family Foundation, grand rounds, James Goldenring, Vanderbilt University Medical Center, VUMC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: